NCBI

Pub Med

My NC

[Sign In] [Regis

All Databases   PubMed   Nucleotide   Protein   Genome   Structure   OMIM   PMC   Journals   Book

Search PubMed for [   ] Go Clear

Limits   Preview/Index   History   Clipboard   Details

Display Abstract   Show 20   Sort by   Send to

All: 1   Review: 0

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: J Endocrinol. 2004 May;181(2):315-25.   Related Articles, Links

Society for Endocrinology
FULL TEXT ONLINE

Divergent roles for ferric ions in the biological activity of amidated and non-amidated gastrins.

Pannequin J, Tantiongco JP, Kovac S, Shulkes A, Baldwin GS.

University of Melbourne Department of Surgery, Austin Campus, A and RMC, Studley Road, Heidelberg, Victoria 3084, Australia.

Amidated forms of the peptide hormone gastrin act via the cholecystokinin-2 receptor to stimulate gastric acid secretion, whereas non-amidated forms stimulate colonic mucosal proliferation via a novel, as yet uncharacterised, receptor. Nuclear magnetic resonance (NMR) and fluorescence spectroscopic studies have revealed that glycine-extended gastrin17 bound two ferric ions, and that ferric ion binding was essential for biological activity. We have therefore investigated the role of ferric ions in the biological activity of amidated gastrin17. As with glycine-extended gastrin17, fluorescence quenching experiments indicated that Glu7 Ala and Glu8,9 Ala mutants of amidated gastrin17 each bound only one ferric ion. The affinity of the mutant peptides for the cholecystokinin-2 receptor on transfected COS-7 cells or on Tlymphoblastoid Jurkat cells, and their potency in stimulation of proliferation in Jurkat cells and inositol phosphate production in transfected COS-7 cells, were similar to the values obtained for amidated gastrin17. In addition, the iron chelator desferrioxamine did not significantly inhibit either binding of amidated gastrin17 to the cholecystokinin-2 receptor, or stimulation of inositol phosphate production by amidated gastrin17 in transfected COS-7 cells. We conclude that, in contrast to glycine-extended gastrin17, binding of ferric ions is not essential for the biological activity of amidated gastrin17. Our results support the concept of distinct modes of action for amidated and non-amidated gastrins, and raise the possibility of developing selective antagonists of the actions of non-amidated and amidated gastrins.

PMID: 15128280 [PubMed - indexed for MEDLINE]

by Satsangi *et al* in the initial analysis.[13] As concluded by Lesage and colleagues[2] further studies are needed to determine if chromosome 12 contains a major disease gene or if the putative gene in this region has only a small influence on the risk of developing IBD.

A third possibility is that we are looking at a population specific difference. Although it appears unlikely that the population in the UK is substantially different from that in France or Belgium, only a repeat study in the UK could clarify this issue. Within our own linkage study[9] much of the power for the weak linkage seen on chromosome 12 resulted from the sib pairs recruited from the UK which would support this theory (unpublished). A consortial analysis, which drew about 50 sib pairs from each sample collected world wide,[22] confirmed linkage to chromosome 12 although at a much lower significance level than that reported initially.

The work of Lesage and colleagues[2] further indicates that linkage to chromosome 12 is not as powerful as initially thought. Identification of the first disease genes for IBD is still eagerly awaited. Although most likely in the distant future, only the definition of the causative mutations will allow a precise construction of a disease model and more exact predictions of the number and influence of additional genetic alterations.

S SCHREIBER

1st Department of Medicine,
Christian-Albrechts-University,
Schittenhelmstrasse 12,
24105 Kiel, Germany
s.schreiber@mucosa.de

1 Hugot JP, Zouali H, Lesage S, *et al.* Etiology of the inflammatory bowel diseases. *Int J Colorectal Dis* 1999;14:2–9.
2 Lesage S, Zouali H, Colombel JF, *et al.* Genetic analyses of chromosome 12 loci in Crohn's disease. *Gut* 2000;47:787–91.
3 Hugot JP, Laurent-Puig P, Gower-Rousseau C, *et al.* Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature* 1996;379:821–3.
4 Ohmen JD, Yang HY, Yamamoto KK, *et al.* Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. *Hum Mol Genet* 1996,5:1679–83.
5 Parkes M, Satsangi J, Lathrop GM, *et al.* Susceptibility loci in inflammatory bowel disease. *Lancet* 1996;348:1588.
6 Cho JH, Fu Y, Kirshner BS, *et al.* Confirmation of a susceptibility locus, IBD 1, for Crohn's disease on chromosome 16. *Inflamm Bowel Dis* 1997;3:186–90.
7 Cavanaugh JA, Callen DF, Wilson SR, *et al.* Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. *Ann Hum Genet* 1998;62:291–8.
8 Curran M, Lau KF, Hampe J, *et al.* Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. *Gastroenterology* 1998;115:1–7.
9 Hampe J, Schreiber S, Shaw S, *et al.* A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. *Am J Hum Genet* 1999;64:808–16.
10 Brant SR, Fu Y, Fields CT, *et al.* American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. *Gastroenterology* 1998;115:1056–61.
11 Mirza MM, Lee J, Teare D, *et al.* Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. *J Med Genet* 1998;35:218–21.
12 Annese V, Latiano A, Bovio P, *et al.* Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus—a GISC study. *Eur J Hum Genet* 1999;7:567–73.
13 Satsangi J, Parkes M, Louis E, *et al.* Two stage genome wide search in inflammatory bowel disease provides evidence for loci on chromosomes 3, 7 and 12. *Nat Genet* 1996;14:199–202.
14 Duerr RH, Barnada M, Zhang L, *et al.* Linkage and association between inflammatory bowel disease and a locus on chromosome 12. *Am J Hum Genet* 1998;63:95–100.
15 Yang H, Ohmen JD, Ma R, *et al.* Linkage and association between Crohn's disease and a putative locus on chromosome 12. *Gastroenterology* 1998;114:A902.
16 Hampe J, Shaw SH, Saiz R, *et al.* Linkage of inflammatory bowel disease to human chromosome 6p. *Am J Hum Genet* 1999;65:1647–55.
17 Rioux JD, Silverberg MS, Daly MJ, *et al.* Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. *Am J Hum Genet* 2000;66:1863–70
18 Kruglyak L, Lander E. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. *Nat Genet* 1995;11:241–7.
19 Kruglyak L, Lander ES. High-resolution genetic mapping of complex traits. *Am J Hum Genet* 1995;56:1212–23.
20 Hampe J, Wienker T, Schreiber S, *et al.* POPSIM: A general population simulation program. *Bioinformatics* 1998;14:458–64.
21 Hampe J, Wienker T, Nürnberg P, *et al.* Mapping genes for inflammatory bowel disease: Considerations for study design in a complex trait. *Hum Hered* 2000;50:91–101.
22 Cavanaugh J for the IBD genetics consortium. The international IBD genetics consortium confirms linkage of Crohn's disease to a locus on chromosome 16 (IBD1). *Gastroenterology* 2000;118:A3862.

Gastrin, growth, and colon neoplasia

The ability of the gastric hormone gastrin to stimulate gut epithelial cell proliferation has been appreciated since the late 1960s.[1] However, aside from the special case of gastric carcinoid tumours arising from enterochromaffin-like cells, the contribution of gastrin to gastrointestinal neoplasia has been uncertain. Several developments now suggest a role for gastrin in both gastric and colorectal cancer. In the case of gastric cancer, recent evidence indicates a synergy between gastrin and *Helicobacter* infection in accelerating progression to atrophy and cancer.[2] Different issues are involved in colorectal cancer. The important emerging concepts here are that (a) the gastrin gene is expressed in colorectal cancer cells, but (b) the main products of gene expression in these cells are not ligands for the gastrin-cholesystokinin receptor B (CCKB), although (c) they do act as colon growth factors. The paper by Smith and Watson[3] now shows that gastrin mRNA, detected by reverse transcription-polymerase chain reaction, is expressed in early stage polyps, that the main forms of gastrin detected by immunohistochemistry are biosynthetic precursor peptides, and that there is also parallel expression of the gastrin-CCKB receptor (see page 820).

It used to be thought that the only biologically active peptides generated from the gastrin gene were COOH terminally amidated peptides such as G34 and G17, and that

carboxy terminal amidation was essential for the biological activity of members of the gastrin family. The amidated gastrins are generated from a precursor, progastrin, via biosynthetic intermediates, the Gly-gastrins (fig 1). Neither progastrin nor Gly-gastrins have a carboxy terminal amide group and therefore they do not have high affinity for the gastrin-CCKB receptor, which is the receptor mediating acid secretory responses to gastrin. It seems, however, that these peptides exhibit other biological properties, notably stimulation of colon cell growth. This effect has been found in both transgenic mice over expressing progastrin and Gly-gastrin, and in colon cancer cell lines.[4–6] The precise receptors mediating the trophic actions of progastrin and Gly-gastrin remain uncertain. It is not clear if there is one (the putative gastrin-CCKC receptor) or several. It is conceivable that a modified version of the gastrin-CCKB receptor, perhaps generated by alternative mRNA splicing, mediates the effects of progastrin and Gly-gastrin; at present this idea is largely speculative. It is unlikely, however, that the progastrin and Gly-gastrin found by Smith and Watson in early stage polyps act at authentic gastrin-CCKB receptors.

The pattern of relatively high abundance of progastrin and Gly-gastrin compared with amidated gastrin that occurs in colonic neoplasms differs markedly from that in normal pyloric antral G cells where the amidated gastrins predominate. There are several plausible explanations for this. There may, for example, be differences in the expression of enzymes required for each conversion step in

Preprogastrin
⇩
Progastrin
⇩
Gly-gastrins
(G34-Gly, G17-Gly)
⇩
Amidated gastrins
(G34, G17)

| Proliferation in colon |

| Differentiation in stomach |

| Proliferation in stomach Histamine synthesis and secretion Acid secretion |

Figure 1 Schematic representation of the pathway of gastrin biosynthesis and the biological properties of the products. Open arrows show the conversion steps by which preprogastrin is converted to amidated gastrins. This sequence of events is completed in G cells but in colorectal cancer cells the main products are progastrin and Gly-gastrin. Progastrin and Gly-gastrins stimulate colon proliferation. Amidated gastrins play a minor role in control of colon proliferation but stimulate acid secretion and gastric proliferation via the gastrin-CCKB receptor (at which progastrin and Gly-gastrin have low affinity).

gastrin biosynthesis (fig 1). In normal G cells, the enzymes responsible for production of carboxy terminal amidated gastrins mostly act in vesicles of the so called regulated pathway of exocytosis[7]; but these vesicles are scarce or absent in polyp and adenoma cells. As a consequence, these cells are poorly equipped both to store hormonal peptides and to complete the full sequence of events giving rise to carboxy amidated gastrins. Instead, peptides mostly corresponding to progastrin and Gly-gastrin are likely to pass directly from the Golgi complex to the cell surface by what is known as the constitutive route of secretion.

What regulates gastrin gene expression in colon polyps and adenomas? Studies by Nakata *et al* have shown that oncogenic Ras stimulates the mitogen activated protein kinase pathway and so increases gastrin gene expression.[8] Recently, Koh *et al* demonstrated that the β-catenin/T cell factor 4 pathway also stimulates gastrin gene expression.[9] Acquisition of mutations that activate the latter pathway is likely to be an early event in the progression to colorectal cancer and could account for the increased gastrin gene expression found by Smith and Watson. Whether or not

similar mechanisms account for upregulation of the gastrin-CCKB receptor is not known.

Recently, Singh *et al* reported that mice with elevated plasma progastrin exhibit increased aberrant crypt foci, adenomas, and adenocarcinomas after treatment with azoxymethane.[10] [11] Aberrant crypt foci are considered to be a marker for progression to colon cancer. Singh *et al* suggest progastrin is a cocarcinogen, that is, on its own it is not carcinogenic but it increases the pool of transformed cells and so exacerbates the oncogenic progression. Interestingly, mice with elevated plasma concentrations of amidated gastrin did not exhibit increased aberrant crypt foci, adenomas, or carcinomas in response to azoxymethane. The picture emerges then that mutations acquired early in the progression to colorectal cancer lead to increased local production of progastrin and Gly-gastrin that then act as auto- or paracrine growth factors expanding the number of transformed cells. This analysis leaves open the role of the gastrin-CCKB receptor, and further work will certainly be needed on this point. Whether or not these findings can be developed into novel therapeutic strategies will depend on characterisation of the receptor mechanisms mediating the effects of progastrin or Gly-gastrin on colon epithelial proliferation.

G J DOCKRAY

Physiological Laboratory,
University of Liverpool, Crown St,
PO Box 147, Liverpool L69 3BX, UK
g.j.dockray@liverpool.ac.uk

1 Johnson LR. Regulation of gastrointestinal mucosal growth. *Physiol Rev* 1988;68:456–502.
2 Wang TC, Dangler CA, Chen D, *et al.* Synergistic interaction between hypergastrinemia and *Helicobacter* infection in a mouse model of gastric cancer. *Gastroenterology* 2000;118:36–47.
3 Smith AM, Watson SA. Gastrin and gastrin receptor activation—an early event in the adenoma carcinoma sequence. *Gut* 2000;47:820–4.
4 Wang TC, Koh TJ, Varro A, *et al.* Processing and proliferative effects of human progastrin in transgenic mice. *J Clin Invest* 1996;98:1918–29.
5 Koh TJ, Dockray GJ, Varro A, *et al.* Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. *J Clin Invest* 1999;103:1119–26.
6 Hollande F, Imdahl A, Mantamadiotis T, *et al.* Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. *Gastroenterology* 1997;113:1576–88.
7 Varro A, Henry J, Vaillant C, *et al.* Discrimination between temperature- and brefeldin A-sensitive steps in the sulfation, phosphorylation, and cleavage of progastrin and its derivatives. *J Biol Chem* 1994;269:20764–70.
8 Nakata H, Wang S-L, Chung DC, *et al.* Oncogenic ras induces gastrin gene expression in colon cancer. *Gastroenterology* 1998;115:1144–53.
9 Koh TJ, Bulitta CJ, Fleming JV, *et al.* Gastrin is a downstream target of the β-cantenin/TCF-4 signaling pathway which mediates growth in the APC^min-/+ mouse model of intestinal polyposis. *J Clin Invest* 2000;106:533–9.
10 Singh P, Velasco M, Given R, *et al.* Progastrin expression predisposes mice to development of colon carcinomas and adenomas in response to AOM. *Gastroenterology* 2000;119:162–71.
11 Singh P, Velasco M, Given R, *et al.* Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM. *Am J Physiol Gastrointest Liver Physiol* 2000;278:G390–9.

Alcohol and retinoid metabolism

The complex interactions between the metabolism of retinoids and ethanol have been reported for a long time. Clinically, chronic ethanol consumption leads to vitamin A deficiency but also to enhanced toxicity of vitamin A and beta-carotene when supplemented. Changes in retinol metabolism due to alcohol may have a pathophysiological impact in both alcoholic liver disease and alcohol associated cancer as retinoic acid, the most active form of vitamin A, is an important regulator of normal epithelial cell growth, function, and differentiation. Under normal conditions, ingested retinol is metabolised to retinaldehyde

via cytosolic alcohol dehydrogenase (ADH), microsomal retinol dehydrogenase (three types), and several types of cytosolic retinol dehydrogenases, and retinaldehyde is further oxidised to retinoic acid via aldehyde dehydrogenase (ALDH). Retinoic acid binds to retinoic acid receptors (RAR), initiating intracellular signal transduction leading to a cascade of events and finally to a decrease in cell regeneration. The main molecular action of retinoic acid involves either transactivation through direct binding to retinoic acid response elements (RARE) in target gene promoters, thereby transcriptionally activating a series of genes with distinct antiproliferative activity, or transrepression of activator protein (AP-1) and regulation of apoptosis. It is not surprising that this complex interaction between ethanol and metabolism of retinoids occurs as